Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release

1P2-15496945

Publication: U.S. Newswire

Date: 2008-03-12 00:00:00

To: MEDICAL EDITORS

Contact: Carole Copeland of Eli Lilly and Company, +1-317-277- 3661, +1-317-610-6196 mobile

INDIANAPOLIS, March 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY), strongly disagrees with the characterization of company practices as alleged by the Connecticut Attorney General Richard Blumenthal in a news release issued March 11, 2008.

The tone and content of the release is a disservice to patients who may currently be taking Zyprexa to treat a life-threatening disease. Specifically, the news release contained ...

To read the rest of the article, click here to take a free trial!